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Abstract
African trypanosomiasis is a deadly neglected disease caused by the extracellular parasite
Trypanosoma brucei. Current therapies are characterized by high drug toxicity and increas-
ing drug resistance mainly associated with loss-of-function mutations in the transporters in-
volved in drug import. The introduction of new antiparasitic drugs into therapeutic use is a
slow and expensive process. In contrast, specific targeting of existing drugs could represent
a more rapid and cost-effective approach for neglected disease treatment, impacting
through reduced systemic toxicity and circumventing resistance acquired through impaired
compound uptake. We have generated nanoparticles of chitosan loaded with the trypanoci-
dal drug pentamidine and coated by a single domain nanobody that specifically targets the
surface of African trypanosomes. Once loaded into this nanocarrier, pentamidine enters try-
panosomes through endocytosis instead of via classical cell surface transporters. The cura-
tive dose of pentamidine-loaded nanobody-chitosan nanoparticles was 100-fold lower than
pentamidine alone in a murine model of acute African trypanosomiasis. Crucially, this new
formulation displayed undiminished in vitro and in vivo activity against a trypanosome cell
line resistant to pentamidine as a result of mutations in the surface transporter aquaglycero-
porin 2. We conclude that this new drug delivery system increases drug efficacy and has
the ability to overcome resistance to some anti-protozoal drugs.
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Author Summary
Drug resistance is complicating the treatment of parasitic diseases including African trypano-
somiasis, a fatal disease if left untreated. Development of a vaccine is unlikely due to parasite
antigenic variation. Current chemotherapy relies primarily on four drugs. Three of these
drugs access the cell’s interior through surface transporters and resistance mechanisms are
largely associated with loss-of-function mutations in the involved surface drug transporters.
We reasoned that using an alternative drug entrance would circumvent parasite resistance
due to mutation in a surface transporter. We have developed a drug nanocarrier that consists
of polymeric nanoparticles coated with a single domain antibody that targets the trypanosome
surface. This new formulation reduces the minimal curative dose and, most importantly, cir-
cumvents drug resistance in a resistant cell line as a result of mutations in the surface trans-
porter that mediate drug uptake. This study presents a proof-of-concept of a novel technology
for reversing transporter-related drug resistance with applications to other infectious diseases.
Introduction
Human African trypanosomiasis, also known as sleeping sickness, is caused by the flagellated
protozoa T. b. gambiense and T. b. rhodesiense, which are transmitted by tsetse flies of the
genus Glossina from human and/or animal reservoirs [1–2]. Trypanosomes evade their hosts’
humoral immune response through continuous variation of the variant surface glycoprotein
through a process called antigenic variation, hampering the generation of conventional vac-
cines [3]. Therefore, treatment of African trypanosomiasis with chemotherapy is the only via-
ble control option. HAT chemotherapy relies primarily on four drugs: pentamidine, suramin,
melarsoprol and, most recently, eflornithine/nifurtimox combination therapy (NECT) [4]. All
of them have limitations, ranging from problems with poor efficacy and acute toxicity to drug
resistance [5].One of the most promising new therapeutic approaches for improved chemo-
therapy focuses on the design of polymeric nanostructures as drug delivery systems. Chitosan
is a biodegradable and biocompatible compound obtained by partial deacetylation of the natu-
ral polymer chitin. Chitosan may be prepared as nanoparticle (NP) drug carriers functionalized
with agents such as polyethylene glycol (PEG). Targeted delivery of nanoparticles enhances the
effectiveness of the treatment, minimizes toxicity and prevents drug metabolism and elimina-
tion [6]. Active targeting and delivery can be achieved by coupling ligands or antibodies onto
the surface of the NPs. For example, the single-domain antibodies (called nanobodies) are
small antibodies fragments, derived from camelids heavy chain antibodies through recombi-
nant gene technology, with unique antigen recognition properties; they can be used to target bi-
ological structures or specific cell types [7], including African trypanosomes [8–9].
Here we have developed a new polyvalent drug delivery system for the treatment of African
trypanosomiasis based on PEGylated chitosan nanoparticles coated with a nanobody that spe-
cifically recognizes conserved cryptic epitopes on the parasite surface [8]. Nanoparticles were
loaded with the trypanocidal drug pentamidine and its effectiveness was assayed in vitro and in
vivo against T. brucei and a pentamidine resistant cell line.
Results and Discussion
Generation and characterization of the drug delivery system
We designed a nanocarrier for drugs, consisting of pentamidine-loaded functionalized PEGy-
lated-chitosan nanoparticles, coated by a single-domain antibody (nanobody) derived from
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camel heavy-chain antibodies, which targets the surface of T. brucei [8–9]. More precisely, this
nanobody, known as NbAn33, specifically recognizes a conserved N-linked high mannose oli-
gosaccharide present in most VSGs [8–10]. The nanobody epitope is located close the parasite
surface membrane, inaccessible for large molecules such as conventional antibodies. Hetero-
functional PEG chains were employed to link NbAn33 to chitosan NPs. The molecular weight
of the PEG used, 3 kDa, was an important parameter in the design of the nanocarrier. As previ-
ously reported [11], its chain length (26 nm) allows the nanobody linked to the NPs to reach its
recognition epitope concealed within the densely packed VSG surface coat (about 10–15 nm
thick) acting as an anchor rope for the nanoparticle.
Pentamidine-loaded functionalized PEGylated-chitosan nanoparticles coated by NbAn33,
NbAn33-pentamidine-chNPs, were generated by a coacervation method [12] which allowed
the generation of well-stabilized spherical NPs with an average size of ~ 135 nm in diameter
[13–15] (S1 Table). A Zeta (z) potential value analysis showed no substantial differences be-
tween the surface charge properties of pentamidine loaded NPs and empty NPs, indicating that
pentamidine was trapped inside NPs rather than just absorbed at the surface (S1 Table). PEGy-
lation of chitosan NPs was qualitatively confirmed by nuclear magnetic resonance. The maxi-
mum pentamidine concentration loaded into NPs, expressed as entrapment efficiency and
drug loading capacity, was 67% and 23%, respectively. The in vitro characterization of pentam-
idine release showed a biphasic profile at physiological pH: 40% of the encapsulated pentami-
dine was rapidly released within the first 12 h, while the remaining 60% was released at a
constant rate during the following ~5 days (S1 Fig). Interestingly, the NPs showed a pH-re-
sponsive drug release (S1 Fig), likely due to swelling/degradation of the NP matrix at acid pH.
This behaviour may be advantageous for the intracellular delivery of pentamidine in acidic
compartments. Finally, results from blood compatibility studies indicated a broad in vivo safety
margin for all the nanoparticulate formulations (S2 Table).
In vitro trypanotoxicity studies
The-inhibitory concentration (IC50) value of free pentamidine for bloodstream trypanosomes
was 9.6 ± 0.3 nM (Fig 1A). The trypanolytic effect of pentamidine was significantly improved
when it was loaded into NbAn33-pentamidine-chNPs. The IC50 value was 0.69 nM, which rep-
resents an approximately 14-fold reduction in drug concentration relative to free pentamidine
(P<0.0001) (Fig 1A). To evaluate the contribution of NbAn33 to nanoparticles efficacy, the ef-
fect of pentamidine-loaded PEGylated chitosan nanoparticles (pentamidine-chNPs) that had
not been coated by the NbAn33 was tested in parallel. The trypanocidal activity of non-coated
NPs was still higher than free pentamidine (IC50 value of 1.94 nM; P<0.0001, versus free pent-
amidine) but lower than NbAn33-pentamidine-chNPs (P<0.0001) (Fig 1A). One factor in the
relative effectiveness of the uncoated NPs compared to free pentamidine may be the electro-
static interactions between positively charged nanoparticles with the slightly negatively charged
surface of the bloodstream forms. As expected, neither unloaded PEGylated chitosan nanopar-
ticles (chNPs-empty) nor empty nanobody-coated PEGylated-chitosan nanoparticles
(NbAn33-chNPs) had any effect on parasite viability (S2 Fig).
In vivo therapeutic studies
The minimal full curative dose of pentamidine in a mouse model of acute infection of T. brucei
was previously established as four doses of 2.5 mgkg-1 administrated daily by intraperitoneal
injection in four consecutive days, starting upon detection of parasites in blood (day 3 after in-
fection) [16–17] and this was also curative in our model of infection (Fig 1B). Mice were intra-
peritoneally infected with 104 parasites. In the group of mice treated with a 10-fold lower dose
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of free pentamidine (4×0.25 mgkg-1) the parasites disappeared from the peripheral blood after
the third dose (Fig 1C). However, the infection relapsed and the mice began to die at day 22
after infection, curing only 20% of the treated animals (Fig 1B).
Having established the suboptimal pentamidine curative dose (4×0.25 mgkg-1), we treated
mice with an equal dose of pentamidine loaded into NbAn33-chNPs. Clearance of parasites
from this group was complete after the first dose and the treatment successfully cured 100% of
the animals (Fig 1B and 1C). Infected mice were also treated with the same pentamidine dose
loaded into chNPs that were not coated with the nanobody. In this group parasites disappeared
from the blood after the first dose, however 40% of the treated mice succumbed to the infection
(Fig 1B and 1C). Next, a dose that was 100-fold lower than the minimal curative dose of pent-
amidine was tested. At that low dosage (4×0.025 mgkg-1), free pentamidine did not cure any
of the mice from trypanosome infection. Although the parasitemia levels increased less rapidly
than in vehicle treated mice the parasites never disappeared from the blood and all mice died
Fig 1. Sensitive profile of T. brucei bloodstream forms. (a) IC50 analysis. Pentamidine (grey column); pentamidine-loaded PEGylated chitosan
nanoparticles (pentamidine-chNPs, red column) and nanobody-coated pentamidine-loaded PEGylated chitosan nanoparticles (NbAn33-pentamidine-
chNPs, blue column). Errors bars indicate S.D. from 3–9 independent experiments. Statistical significance was ***, p<0.001. (b) Therapeutic effect in T.
brucei acute infection mouse model. Survival (Kaplan-Meier plot) of female C57BL/6J mice infected with T. brucei AnT1.1 (1 x 104 parasites). The treatment
started once the parasites were detected in blood, at the 3rd day after inoculation and consisted in a daily dose in four consecutive days. Treatment with
pentamidine, pentamidine-chNPs, NbAn33-pentamidine-chNPs, NbAn33-chNPs empty (nanobody-coated non pentamidine-loaded PEGylated chitosan
nanoparticles) and vehicle (physiological saline solution). (c) Parasitemia in T. brucei acute infection mouse model. Treatment with vehicle (physiological
saline solution), NbAn33-chNPs empty (nanobody-coated PEGylated-chitosan nanoparticles), free pentamidine, pentamidine-chNPs (pentamidine-loaded
PEGylated chitosan nanoparticles), NbAn33-pentamidine-chNPs (nanobody-coated pentamidine-loaded PEGylated chitosan nanoparticles).
doi:10.1371/journal.ppat.1004942.g001
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after 7–12 days of infection (Fig 1B and 1C). As observed in vitro, pentamidine loaded into
non coated NPs was more effective than free pentamidine probably as a consequence of a sus-
tainable drug release from the nanoparticles. Remarkably, treatment with 4 doses of NbAn33--
pentamidine-chNPs at 0.025 mgkg-1 was able to eliminate the parasitemia after the second
dose, curing all treated mice (Fig 1B and 1C). However, the same low dose of pentamidine
loaded into chNPs non-coated by the NbAn33, despite clearing the parasites from the blood
after the third dose, did not cure mice, with 100% of the treated animals dying from the infec-
tion (median survival time 22 days).
In order to investigate the circulation kinetics of NbAn33-chNPs injected intraperitoneally, we
compared the percentage of the dose of NbAn33-chNPs in peripheral blood when administered
intraperitoneally versus intravenously. Thus, NbAn33-chNPs labelled with the infrared fluoro-
phore (DY-649) were administered intravenously or intraperitoneally and fluorescence in blood
was measured at various time points. Nanoparticles concentration in blood at 15 min after intra-
venous injection was taken as reference value (100%). About 90% of the NbAn33-chNPs intraper-
itoneally administered was detectable in blood after 60 min post injection (Fig 2). These results
demonstrated that the intraperitoneal route was suitable for NbAn33-chNPs administration.
Uptake of NbAn33-coated NPs in bloodstream trypanosomes
Three previous studies have shown that NbAn33 is internalized by endocytosis in bloodstream
trypanosomes [18–20]. Therefore, one would anticipate that nanoparticles coated by the nano-
body NbAn33 would enter the cell via this route. Nanoparticles uptake was monitored by fluo-
rescence after incubating bloodstream trypanosomes with Alexa-labelled-NbAn33-chNPs at
37°C. As expected, the fluorescence signal concentrates rapidly in the flagellar pocket (FP) (Fig
3A) and after in the endocytic pathway colocalizing with fluorescent tomato lectin, a marker of
this route in bloodstream African trypanosomes [21] (Fig 3A). Moreover, a comparative study
of the trypanocidal actvity of NbAn33-pentamidine-chNPs at 4°C and 37°C showed that at
37°C trypanotoxicity was time dependent (20% and 65% of cell death after 2 and 4 hour of in-
cubation in the presence of pentamidine (30 μM) (Fig 3B). However, no activity was observed
Fig 2. Circulation kinetics of fluorescent chitosan nanoparticles in mousemodel. Percentage of the
initial dose in peripheral blood when injected via intravenous (i.v.) and intraperitoneal (i.p.) vs. time. Error bars
represent the S.D. from 5 mice.
doi:10.1371/journal.ppat.1004942.g002
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at 4°C under the conditions of the experiment. Together, these results indicate that
NbAn33-chNPs internalization depends on the endocytic process.
Effectiveness of pentamidine loaded NbAn33-chNPs in a pentamidine
resistant cell line
Resistance to pentamidine in T. brucei is associated with mutations in cell surface transport
proteins, specifically in the TbAT1/P2-adenosine transporter [22–24] and in the aquaglycero-
porin 2 (AQP2) channel [25–28]. However, pentamidine loaded into nanoparticles coated by
the nanobody NbAn33 is internalized by the endocytic route (Fig 3). We reasoned that this
Fig 3. Endocytosis of NbAn33-chNPs. (a) Bloodstream trypanosomes observed by fluorescence microscopy after incubation with NbAn33-chNPs-Alexa
Fluor 594 (red) and tomato lectin-FITC (TL, green) as described in Materials and Methods. Samples were taken after 2 minutes (bottom panel) and 10
minutes (top panel) of incubation. DNA is stained with DAPI (blue). Regions of colocalization appear yellow in merged images. (b) Parasite viability after
incubation with NbAn33-pentamidine-chNPs at 37° and 4°C for 2 h. Cell death was estimated by propidium iodide staining and FACS analysis at three time
points. Error bars represent the S.D. from three independent experiments. Statistical significance was *, p<0.05; ***, p<0.001.
doi:10.1371/journal.ppat.1004942.g003
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alternative drug entrance would circumvent parasite resistance to the drug. To test the hypoth-
esis that the trypanocidal action of encapsulated pentamidine was not dependent on cell sur-
face transporters, a T. brucei pentamidine-resistant cell line was selected after in vitro exposure
to increasing concentrations of the drug (up to 50 nM). The resistant clonal cell line, designated
TbR25, was genetically and functionally characterized to determine whether resistance was due
to a mutation in one of the known pentamidine transporters in the plasma membrane. The
TbAT1/P2-adenosine transporter gene was amplified from wild type and TbR25 genomic
DNA. No differences in length or sequence were observed between both PCR products. More-
over, no significant change in TbAT1/P2 expression levels was noted by real-time qRT-PCR
analysis between wild type and resistant cell line (Fig 4A). Finally, TbR25 and wild type try-
panosomes were equally sensitive to diminazene aceturate (Fig 4B), another trypanocidal aro-
matic diamidine where uptake is almost exclusively mediated by the TbAT1/P2 adenosine
transporter [29–31] Together, these data demonstrated that the adenosine transporter was not
involved in the resistance to pentamidine in the TbR25 cell line.
We next searched for mutations in the genomic locus encoding the closely related AQP2 and
AQP3 aquaglyceroporins. Interestingly, genomic PCR analysis of the AQP2/AQP3 locus showed
the deletion of AQP2 gene in one allele and an AQP3/AQP2 chimeric gene in the other allele (Fig
4C and S3 Fig). In the chimera AQP3/AQP2 the first 453 nucleotides were from AQP3 and the
remaining 462 nucleotides, from AQP2. In contrast, the AQP3 sequence was intact in both al-
leles. Rearrangements of the AQP2/AQP3 locus resulting in the loss of the wild-type AQP2 gene
loss also occur in the field, where this genotype is associated with melarsoprol treatment failure
[27]. This result was in agreement with the previous observation that loss of AQP2 renders T.
bruceimuch less sensitive to pentamidine [25, 27–28]. Our results thus suggest that the mecha-
nism of acquired resistance to pentamidine in TbR25 cell line was due to the deletion of AQP2 in
one allele and the presence of the chimera AQP3/AQP2 in the other allele (Fig 4D and S3 Fig).
Although a number of chimeric rearrangements in the AQP2/AQP3 have been reported [27–28]
this is the first rearrangement where it is the amino terminal end is of AQP3 and the carboxy-ter-
minal sequence is from AQP2 rather than the other way around. Recently, it has been published
a model of pentamidine permeation through TbAQP2 [32], proposing that three bulky amino
acids, present in the TbAQP3 pore but not in the TbAQP2 pore, help explain the difference in
pentamidine permeation between these otherwise closely-related proteins. According to this
model, the TbR25 rearrangement introduces at least one bulky amino acid, tryptophan 102 of
AQP3, into the pore, restricting the passage of the relatively large pentamidine molecule.
Having established that the resistance mechanism was due to the absence of the wild-type
coding sequence of TbAQP2, we decided to test whether NbAn33-pentamidine-chNPs were
able to circumvent this resistant mechanism by avoiding the classical uptake through trans-
porters. The IC50 value for pentamidine in the pentamidine-resistant strain TbR25 was 115 ± 5
nM (Fig 5A). However, NbAn33-pentamidine-chNPs reduced the IC50 to 9.9 ± 0.7 nM, similar
to the IC50 of the wild type strain to free pentamidine (9.6 ± 0.3 nM). Uncoated pentamidine-
chNPs were also able to reduce the IC50 of TbR25, although only 2.1-fold relative to free pent-
amidine (P<0.001) (Figs 1A and 5A).
Next, we tested whether the new delivery system was able to overcome pentamidine resis-
tance in vivo. As observed for other pentamidine resistant trypanosomes [24, 26], the TbR25
cell line was significantly less virulent than the wild type. In order to establish infection the
mice were subjected to immunosuppression and inoculated with a parasite load 250-fold
higher than required with our standard strain AnTat 1.1. Once infected, the animals were treat-
ed with the curative dose for wild type trypanosomes (four daily doses of 2.5 mgkg-1) of free
pentamidine and its equivalent loaded within the chNPS coated with NbAn33. All mice treated
with free pentamidine died after infection, whereas 60% of the mice survived following
Overcoming Drug Resistance in African Trypanosomiasis
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Fig 4. Characterization of the pentamidine resistant strain TbR25. (a) Relative quantification (RQ) of
TbAT1/P2 expression in wild type AnTat 1.1 and TbR25 strains estimated by qRT-PCR. (b) IC50 value for
diminazene aceturate in the same strains. Error bars indicate S.D. from 3 replicates. (c) Schematic illustration
of the AQP2/AQP3 locus showing the heterozygote character of TbR25 strain with a chimeric gene in one
allele and the complete deletion of AQP2 gene and the intergenic region in the other (deletion from position
3441867 to 3443663 in chromosome 10, -Tb927_10_v5).
doi:10.1371/journal.ppat.1004942.g004
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treatment with NbAn33-pentamidine-chNPs, and the mice that did succumb to the infection
lived substantially longer than those treated with free pentamidine (Fig 5B). The difference ob-
served in NbAn33-pentamidine-chNPs effectiveness in TbR25 resistant cell line compared to
wild type might be related to the loss of virulence and the fact that mice were immunosup-
pressed before TbR25 infection with 250 times higher parasite load. The cause of this loss of
virulence is not known but is independent of mutations in the AQP2 genes since such muta-
tions are present in field isolates [27]. Therefore, the virulence attenuation phenotype of TbR25
is likely to be associated to laboratory-selected T. bruceimutants.
For the continued treatability of African trypanosomiasis, as for many other infectious dis-
eases, the emergence and spread of drug resistance is the major concern together with the ab-
sence of vaccines. Most of trypanocidal drugs do not diffuse freely across parasite cell
membrane, but several transporters are responsible for their uptake, thereby making a crucial
Fig 5. Sensitive profile of the pentamidine resistant strain TbR25. (a) IC50 analysis. Free pentamidine
(grey column); pentamidine-chNPs (red column) and NbAn33-pentamidine-chNPs (blue column). Errors bars
indicate SEM from 3–9 independent experiments. Fold reductions are indicated in the graph. (b) Therapeutic
effect in TbR25 acute infection mouse model. Survival (Kaplan-Meier plot) of female C57BL/6J mice infected
with TbR25 (inoculum 2.5 x 106 parasites).
doi:10.1371/journal.ppat.1004942.g005
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contribution to their selectivity [33–34]. In African trypanosomes, resistance mechanisms have
generally been associated with mutations that reduce drug import, through loss of function or
changes in substrate selectivity. Notably, there is currently little evidence for the involvement
of drug export transporters such as multi-drug resistance-associated carriers in acquired drug
resistance, as observed for other protozoa such as Plasmodium and Leishmania spp [35–36]. A
recent genomic-scale screening has linked most of the current HAT drugs to specific genes en-
coding surface proteins involved in their uptake [22], confirming some previous results. Eflor-
nithine resistance was associated with loss of amino acid transporter family member AAT6
[22, 37–38], suramin was linked to invariant surface glycoprotein ISG75, melarsoprol to adeno-
sine transporter TbAT1/P2 [38–41], pentamidine to P-type H+-ATPases that maintain the
proton-motive force across the plasma membrane, and pentamidine/melarsoprol cross-resis-
tance to aquaglyceroporins, specifically to aquaglyceroporin 2, which encodes the High Affinity
Pentamidine Transporter (HAPT1) and controls the susceptibility to both drugs [25, 27–28].
The use of chitosan nanoparticles-based therapy allows drug release to be tailored to the
specific target site through the choice of various polymer and copolymer combinations and for-
mulation procedures [42–43]. When the nanocarrier was designed, all possible parameters that
could influence the grade of success of our nanodevice were taken into account. One of the
most important was the pathway that the nanocarrier has to follow to deliver the drug. As
shown in Fig 3A, once the nanoparticles reach the surface of the parasite they are taken up by
endocytosis in the flagellar pocket. Along the endocytic pathway the pH is decreasing, reaching
the lowest value (~pH 5) in the lysosome. Previous reports comparing different polymeric NPs
have concluded that drug release from chitosan NPs is pH dependent [44], making chitosan a
suitable polymer for this specific nanocarrier.
Pentamidine-loaded poly (D,L-lactide) and polymethacrylate nanoparticles have been pre-
viously used against Leishmania (L. infantum and L.major) [45–47]. Pentamidine-loaded
nanoparticles were between 3.3 and 6 times more effective than free pentamidine against Leish-
mania in a murine model vivo. By contrast, NbAn33-pentamidine-chNPs were 100 times
more effective than free pentamidine against T. brucei in vivo. However, these results are not
directly comparable because Leishmania is an intracellular parasite while T. brucei is extracellu-
lar. Another crucial difference is the use of the nanobody NbAn33 for active targeting which
notably increases the effectiveness of the formulation as shown in this study.
In summary, the development of chitosan nanoparticles loaded with current trypanocidal
drugs coated by a specific nanobody against trypanosomes can reduce the minimal curative
dose of these drugs, enhancing their efficacy, minimizing the toxicity and circumventing resis-
tance mechanisms associated to mutation in surface transporters. The significance of the report
is not limited to a single nanobody used to demonstrate the technology, nor to a single drug,
nor indeed to trypanosomiasis. Due to its versatility, the possibilities that offer this targeted
nanobody-system are enormous as it can be adapted to encapsulate any substance with a re-
ported biological action. This opens up a plethora of new possible therapies to treat different
infectious diseases. The most urgent issue in the treatment of infectious disease today is that re-
sistance to drugs is spreading much faster than new drugs are being developed and approved.
The use of encapsulated, nanobody-targeted drugs as described here has the potential to re-
verse resistance to many first-line treatments.
Materials and Methods
Ethics statement
All experiments complied with the with the guidelines of the European Convention for the
Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (CETS
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n° 123) and were approved by the Ethics Committee of the Spanish National Research Council
(CSIC, file UEA2011/JAGS/1).
Parasites
Bloodstream forms of monomorphic T. brucei AnTat 1.1 strain (Institute of Tropical Medicine,
Belgium) were grown in axenic culture at 37°C and 5% CO2 in HMI-9 medium supplemented
with 20% heat-inactivated foetal bovine serum (Gibco) [48].
Nanobody NbAn33
The nanobody NbAn33 used in this study was selected as previously described [8]. NbAn33
recognizes a glycosylated (Man9–5GlcNAc2) epitope on T. brucei VSGs, as indicated by its
binding to synthetic Man9 and Man7 and by its competition for binding with concanavalin A
[8]. Accordingly, NbAn33 binds equally well to several VSGs, such as the MiTat 1.1, MiTat 1.4,
MiTat 1.5 and ETat 1.2 VSGs, which represent different VSG classes and share the conserved
N-linked Man5–9 carbohydrate [8–9].
Preparation of nanobody-coated pentamidine-loaded functionalized
PEGylated-chitosan nanoparticles
For the synthesis of copolymer chitosan-graft-PEG (chitosan-g-PEG), chitosan hydrochloride
(80 mg) was dissolved in 11.5 mL of filtered deionized water. To which MeO-PEG-CH2CO2H
(14.2 mg) and N-hydroxysuccinimide (NHS, 1.6 mg) were added. 1-ethyl-3-(3-dimethylami-
nopropyl) carbodiimide (EDC, 21.7 mg) was then added gradually and the resulting solution
was stirred at room temperature for 22 h. The solution was ultrafiltered (0.22 μm pore size)
and lyophilized.
PEGylated chitosan nanoparticles were prepared by a coacervation method avoiding the use
of toxic organic solvents [13–15]. Briefly, the copolymer chitosan-g-PEG (1%, w/v) was dis-
solved in 10 mL of an aqueous solution of acetic acid (2%, v/v). Next, pluronic F-68 and pent-
amidine (isethionate salt, Sigma) were added at increasing concentrations up to 2% (w/v) and
0.01 M, respectively. Approximately 2.5 mL of a solution of sodium sulphate (20%, w/v) was
added drop wise (0.5 mLmin-1) to the chitosan solution under mechanical stirring (2,000
rpm). The stirring was continued for 1 h to ensure the formation of pentamidine loaded func-
tionalized PEGylated-chitosan nanoparticles (pentamidine-chNPs). The newly formed pent-
amidine-chNPs were cleaned by 3 consecutive cycles of centrifugation for 30 min at 11,000
rpm in a Centrikon T-124 high-speed centrifuge (Kontron) and re-dispersion in double-dis-
tilled water until the conductivity of the supernatant was 10 μScm-1, measured in a Crison
micro pH 2001 conductometer (Crison). Finally, nanobody NbAn33at 1 mgmL-1 was added
to the pentamidine-NPs suspension (10:1 weight ratio) in 10 mL of phosphate buffered saline
(PBS, pH 7.4) containing EDC and NHS. The reaction was left for 3 h at 25°C under mechani-
cal stirring (200 rpm). The resulting NbAn33-coated pentamidine-chNPs (NbAn33-pentami-
dine-chNPs) were submitted to a single wash cycle by centrifugation for 30 min at 11,000 rpm
in a Centrikon T-124 high-speed centrifuge (Kontron) and suspended in 10 mL of physiologi-
cal saline solution (0.09%w/v NaCl). Non-pentamidine loaded nanoparticles (NbAn33-chNPs)
were prepared in parallel.
Nanoparticles characterization
Mean particle diameter (± standard deviation, S.D.) was determined by photon correlation
spectroscopy (PCS) using a Malvern 4700 analyzer (Malvern). The scattering angle was set at
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60° and the measurement was made after suitable dilution of the aqueous nanoparticle suspen-
sions (0.1%, w/v). The stability of the formulations was evaluated by measuring the size of the
particles after 1 month of storage at 4°C in water.
The electrophoretic mobility measurements can qualitatively distinguish the mode of pent-
amidine association with the NPs: encapsulation within the NP matrix or adsorption on the
NP surface. Briefly, the measurements were performed in 0.1% (w/v) aqueous suspensions of
NbAn33-chNPs and NbAn33-pentamidine-chNPs in 1 mM KNO3 pH 6 using a Malvern Zeta-
sizer 2000 electrophoresis device (Malvern). Measurements were performed after 24 h of con-
tact of NPs in water under mechanical stirring (50 rpm) at 25°C. The experimental uncertainty
of the measurements was below 5%. The electrophoretic mobility was converted into zeta po-
tential (zmV) values as described by O’Brien and White [13].
Quantification of pentamidine loaded into the chitosan nanoparticles
Ultraviolet-visible spectrophotometry (UV—Vis) was used to quantify the amount of pentami-
dine loaded into NPs at a wavelength of 261 nm in a 8500 UV-Vis Dinko spectrophotometer
(Dinko). The spectrophotometric method employed was validated by ultra-high-pressure liq-
uid chromatography and mass spectrometry (UPLC-MS) in an Acquity UPLC/QTOF Synapt
G2 (Waters). After NbAn33-pentamidine-chNPs synthesis, the supernatant was obtained by
double centrifugation for 30 min at 11,000 rpm and 25°C in centrifuge machine Centrikon T-
124 high-speed centrifuge (Kontron) and the amount of pentamidine was measured in tripli-
cate. Drug incorporation to NPs was expressed in terms of pentamidine entrapment efficiency
(%) (encapsulated drug [mg]/total drug in the NP suspension [mg] × 100) and pentamidine
loading (%) (encapsulated drug [mg]/carrier [mg] × 100).
In vitro release studies of pentamidine from chitosan nanoparticles
The study of pentamidine release was performed using the NbAn33-pentamidine-NPs with
the maximal loading and entrapment efficiency reached (~23% and ~ 66%, respectively, S1
Table). The assay was performed at 37°C in triplicate following the dialysis bag method using
Spectra/Por 6 dialysis membrane tubing (Spectrumlabs). The release medium for neutral and
acidic conditions was PBS at pH 7.4 and pH 5 respectively. The dialysis bag with pore size 2000
Da retained the NPs, but allowed the free pentamidine to diffuse through the membrane into
the release medium. Briefly, 1 mL of nanoparticle suspension (containing 0.35 mgmL-1 of
pentamidine) was pipetted into the bags, and the two ends fixed by clamps. The bags were then
placed in a conical flask filled with 100 mL of the receiving phase, and were stirred at 200 rpm.
Samples of 1 mL were taken at different times (0.5 h, 1 h, 3 h, 6 h, 9 h and 24 h, and 2, 3, 4 and
5 days) and analyzed for pentamidine content by UV—Vis spectrometry at 261 nm. To main-
tain dialysis conditions an equal volume of the release medium at 37°C was added after taking
each sample.
Blood compatibility and cytotoxicity
The interaction of control (pentamidine unloaded) PEGylated chitosan nanoparticles,
NbAn33-chNPs, pentamidine-chNPs, and NbAn33-pentamidine-chNPs, with blood compo-
nents was investigated in triplicate following a well-defined procedure [49]. The in vitro effect
of the nanoparticulate formulations on erythrocyte lysis was evaluated using PBS as negative
control (0% lysis) and the non-ionic surfactant Triton X-100 (1%, w/v) as positive control
(100% lysis) of hemolysis. Briefly, EDTA-anticoagulated blood was centrifuged at 1,500 rpm
for 20 min to remove the plasma fraction. The original volume was then replaced with 150 mM
NaCl. Upon repetition of this step, the final suspension was diluted 1:10 with 100 mM PBS.
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About 100 red blood cellsmL-1 were incubated at 37°C for 2 h with the nanoparticles (0.05%,
w/v) under mechanical stirring (200 rpm), and centrifuged at 1,500 rpm for 20 min. Hemoglo-
bin release was evaluated by measuring the UV absorbance of the supernatant at 545 nm. He-
molysis (%) was determined as ([absorbance of test sample—absorbance of control] / highest
absorbance of positive control) × 100.
Interaction of platelets with nanoparticulate systems may determine their activation (and
aggregation) which generates thrombotic complications and blood incompatibilities. This pro-
cess is quantified by enzyme-linked immunosorbent assay (ELISA) in terms of soluble P-selec-
tin (sP-selectin) release after incubating the nanoparticles with blood. Blood samples were
centrifuged at 1,000 rpm for 20 min to remove platelet-rich supernatant. Then, blood was
again centrifuged and mixed with previously extracted plasma to obtain platelet-rich plasma
(PRP). Platelet-poor plasma (PPP) was obtained by centrifuging the remaining blood at 3,000
rpm for10 min. The PRP was then diluted 1:100 with 1% ammonium oxalate, and adjusted to a
final platelet concentration of 1108 mL-1. A sample of 0.1 mL of PRP was incubated for 1 h
with 50 mg of nanoparticles at 37°C. The supernatant was then centrifuged 10 min at 5,000
rpm. Soluble P-selectin concentration in the plasma was determined using ELISA kit (eBios-
cence,) following to the manufacturer’s indications.
Opsonization of nanoparticles with complement components (i.e., C3a and C5a) leads to
blood clearance by the reticuloendothelial system (RES). Complement activation was quanti-
fied by measuring C3a release upon incubation of the nanoparticles with pooled citrated plas-
ma obtained by blood centrifugation. C3 cleavage was monitored by measuring the formation
of its activated peptide (C3a desArg) with Complement C3a des Arg Human ELISA kit (Enzo).
Plasma clotting time was determined following the Howell’s method that evaluates plasma
recalcification time (PRT). T1/2 max was quantified as the time at which half the saturate (max-
imum) absorbance value was reached. PBS was used as negative control. Each blood sample
was centrifuged at 3,000 rpm, 25 min at 8°C to obtain the PPP. Samples of 0.1 mL of PPP were
incubated with 50 μg of nanoparticles in PBS for 5 min at 37°C in a 96 well plate. Finally, 0.1
mL of 25 mM CaCl2 solution was added and the plasma solution was monitored for clotting by
manually dipping a silicone-coated stainless-steel wire hook into the solution to detect fibrin
threads. Clotting times were estimated as the time at which the first fibrin strand was formed
on the hook.
Trypanotoxicity assay
Trypanotoxicity was determined using an adapted version of the resazurin sodium salt method
[50]. Briefly, exponentially growing parasites (monomorphic T. brucei AnTat 1.1 and pentami-
dine resistant clonal cell line TbR25) were harvested and prepared at an initial density of 2105
trypanosomesmL-1. 50 μL of this trypanosome suspension was added to each well of a flat-bot-
tom 96-well plate containing doubling dilutions of the drugs (50 μL), excepting for two rows
which received only media. Eleven dilution points were tested, ranging from 680 nM to 165
pM in final pentamidine concentration. In the case of diminazene aceturate the range was be-
tween 2 μM and 2 nM. Cultured plates were incubated at 37°C in an atmosphere of 5% CO2 for
20 h before the addition of 20 μL of the colorimetric viability indicator resazurin sodium salt
(Sigma) at 0.5 mM. After a further 4 h of incubation, the reaction was stopped by the addition
of 50 μL of 3% SDS in water. The plates were read on a Tecan Infinite F200 reader (Tecan Aus-
tria GmbH) using an excitation wavelength of 535 nm and an emission wavelength of 590 nm.
The experiment was performed with six replicates per concentration and repeated on at least
four independent occasions. The results of fluorescence were normalized to 100% of the no-
drug control. The IC50 was defined as the concentration of drug required to reduce the
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fluorescence output by 50% and its value was determined by plotting to an equation for a sig-
moid curve with a variable slope, of log (test compound concentration) versus the normalized
fluorescence, using Prism 5 (GraphPad Software). Statistical significance was determined by
unpaired student’s t-test.
For temperature dependent trypanotoxicity assays parasites growing in logarithmic phase
(5×105 cellmL-1) were treated with NbAn33-pentamidine-chNPs (30 μM of final pentamidine)
at 37°C and 4°C respectively. Samples (5×105 cells) taken at three different set time points were
incubated on ice for at least 5 min, washed with phosphate-buffered saline (PBS) and incubated
with propidium iodide (PI) staining solution (PBS containing 40 μgmL-1 PI and 100 μgmL-1
ribonuclease A) for at least 20 min on ice. The experiment was performed in parallel with un-
treated parasites as a control. The analysis was performed with a BD FACScanto II flow cytom-
eter (BD Biosciences) and FlowJo software. The experiment was performed in triplicate and
repeated at least three times.
In vivo therapy experiments
Animal experimental protocols were approved by the Ethics Committee of the Spanish Council
of Scientific Research (CSIC). The drug delivery system NbAn33-pentamidine-chNPs was test-
ed in vivo against the monomorphic AnTat1.1 strain using a modification of the approach pre-
viously described [16–17]. Briefly, five female C57BL/6J mice (8-week-old; Jackson
Laboratories) per group were intraperitoneally infected with 104 parasites each. Once parasites
were detected in the blood, at day 3 after infection, the mice were treated daily on four consecu-
tive days with i.p. injections of pentamidine in physiological saline solution. The dosages used
for each group were pentamidine 2.5 mgkg-1; pentamidine 0.25 mgkg-1; pentamidine 0.025
mgkg-1; NbAn33-pentamidine-chNPs 0.25 mgkg-1; NbAn33-pentamidine-chNPs 0.025
mgkg-1; pentamidine-chNPs 0.25 mgkg-1 and pentamidine-chNPs 0.025 mgkg-1 (drug con-
centrations mgkg-1 were calculated considering the molecular weight of the isethionate salt).
Two control mice groups were either left untreated (injected with the same volume of physio-
logical saline solution) or received pentamidine-free NbAn33-chNPs. We followed the parasi-
temia by counting the number of trypanosomes in tail-vein blood with an optical microscope
with a Neubauer chamber every day during the first week, and afterwards, once per week until
60 days post-infection. Parasite survival was monitored and recorded every day until 60 days
post-infection. Mice were considered cured when there was no parasitemia relapse detected in
the 60 days period. Animals were humanely sacrificed when they showed severe clinical signs
or when the parasitemia reached 108 parasitesmL-1.
Circulation kinetics of nanoparticles
Fluorescent NbAn33-chNPs were generated as previously described [51] with some modifica-
tions. Briefly, 0.5 mL of NbAn33-chNPs (1 mgmL-1) were fluorescently labeled with 0.18 mM
(0.2 mg) of Dy649-NHS (NbAn33-chNPs-Dy649) (Dyomics GmbH) in phosphate buffered sa-
line (PBS) at RT for 45 min. Labeled NP were washed three times by centrifugation at 14,000 g
for 30 min and resuspended in PBS at a final concentration of 1 mgmL-1.
Mice were administered with 0.1 mg of NbAn33-chNPs-Dy649 (1 mgmL-1) intravenously
and intraperitoneally. At various time points (15 min, 30 min, 45 min, 60 min, 4 h, 24 h and 48
h), 5 μL of blood was collected from the tail and immediately diluted in 200 μL Hanks’ Bal-
anced Salt solution (pH 7.4). The fluorescence of blood samples was measured in a plate reader
(excitation 655 nm, emission 676 nm) and correlated with a standard curve of
NbAn33-chNPs-Dy649 in whole blood.
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In vitro generation of T. brucei resistant cell line
T. brucei AnTat 1.1 bloodstream forms (5×104 cellsmL-1) were growth in a 24-well plate in the
presence of increasing concentrations of pentamidine, ranging from 1 nM to 10 nM. The high-
est concentration of pentamidine at which growth was detected was 1 nM. Parasites growing at
this concentration were diluted to 5×104 cellsmL-1 and sub-cultured into two new wells with
fresh medium containing one and half and double the drug concentration, respectively. When
cells were growing at 50 nM at a rate comparable to the original (wild type) strain they were di-
luted to an average density of 0.3 cellsmL-1 and cultured in a 24 wells plate. Ten clones grew
and five were selected for further DNA and RNA content analysis.
In vivo therapy experiments in a pentamidine resistant cell line
Mice were first immunosuppressed with 200 mgkg-1 of cyclophosphamide (Sigma) and in-
fected the next day with 2.5×106 parasites of TbR25. After ten passages in mice to adapt the re-
sistant cell line to the host, 25 female C57BL/6J mice (6-week-old; Jackson Laboratories) were
intraperitoneally injected with cyclophosphamide and infected with 2.5×106 parasites the next
day. Once parasites were detected in blood samples, at day 1 post infection, mice were treated
daily on four consecutive days. The dosages used for each group were pentamidine 2.5 mgkg-1;
pentamidine 0.25 mgkg-1; NbAn33-pentamidine-chNPs 2.5 mgkg-1 and NbAn33-pentami-
dine-chNPs 0.25 mgkg-1. Control mice were left untreated (physiological saline injections).
Parasitemia and survival were monitored as described for infection with wild type AnTat1.1.
Animals were humanely sacrificed when showing severe clinical signs or when the parasitemia
reached 108 parasitesmL-1.
Nanoparticles uptake
NbAn33-chNPs (1 mL at 1 mgmL-1) were labelled using the Alexa Fluor 594 Protein labeling
kit (Invitrogen), in 5 mM KCl, 80 mMNaCl, 1 mMMgSO4, 20 mMNa2HPO4, 2 mM
NaH2PO4, pH 7.4) at room temperature for 1 h. Labelled NP were washed three times by centri-
fugation at 14,000 g for 30 min and resuspended in 5 mM KCl, 80 mMNaCl, 1 mMMgSO4, 20
mMNa2HPO4, 2 mMNaH2PO4, 20 mM glucose, pH 7.4, at a final concentration of 1 mgmL-1.
Live bloodstream forms (106 cellsmL-1) were incubated in 5 mM KCl, 80 mMNaCl, 1 mM
MgSO4, 20 mMNa2HPO4, 2 mMNaH2PO4, 20 mM glucose, pH 7.4 (TDB) with Alexa 594 la-
belled NbAn33-chNPs (50 μgmL-1) for 10 min at 37°C. NPs excess was removed by centrifuga-
tion at 4°C. Parasites were resuspended in TDB with tomato lectin-FITC conjugate (Sigma) at
20 μgmL-1, incubated for either 2 or 10 min at 37°C and then fixed in 4% paraformaldehyde in
PBS for 1 h at 4°C. Finally, trypanosomes were washed with PBS three times, spread on poly-L-
lysine-coated slides, and mounted in DAPI-containing Vectashield medium (Vector Laborato-
ries). For fluorescence microscopy analysis image acquisition was performed with a LSH 710
Confocal Microscope (Zeiss) and image analysis with ZEN 2012 (Zeiss) software.
Genotyping
Genomic DNA was extracted using DNAzol reagent (Invitrogen), according to the manufac-
turer’s protocol. The TbAT1/P2 complete open reading frame (TriTrypDB Tb927.5.286b) was
amplified by PCR using the specific primers AT1F (5’ ATG CTC GGG TTT GAC TCA GC 3’)
and AT1R (5’ CTA CTT GGG AAG CCC CTC AT 3’) [52]. The PCR was performed with
AccuTherm DNA polymerase (Genecraft Germany) with the followings parameters: 1 cycle of
95°C for 2 min and 35 cycles of (95°C, 50 s; 50°C, 50 s; 72°C, 2.5 min). PCR products were run
on a 1% agarose gel and purified on a silica membrane column (Nucleospin gel and PCR clean
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up, Macherey Nagel). The purified PCR products were directly sequenced with the same prim-
ers as used for PCR amplification.
The AQP2 (TriTrypDB Tb927.10.14170) and AQP3 complete genomic sequences (Tri-
TrypDB Tb927.10.14160) were amplified with AccuTherm DNA polymerase using the forward
primer AQP2/3F (5' GCT CCA GAA AAT CAG AAT GC 3') and the reverse primers AQP2R
(5' GCG AAG GGT ATT GAC GGT TA 3') and AQP3R (5' GTG CCA CAC TAA TCT GCA
TG 3'), respectively. The PCR conditions were: 1 cycle of 95°C for 2 min and 35 cycles of (95°C,
50 s; 47°C, 50 s; 72°C, 2.5 min). The PCR products were purified and sequenced. Two internal
forward primers were designed to confirm the chimeric AQP2/AQP3 sequence; AQP2Fi (5'
GAG CGG TGG GAT GCA GAT G 3') and AQP3Fi (5' CGC CAC GGT TAT CAT TGA TGG
G 3'). TbAQP3/TbAQP2 sequence was submitted to GenBank; accession number KR059026.
The complete AQP2-AQP3 locus was amplified using the forward primer SEC13 (5’ CAAAAT-
CAGCGGGTTCACTG 3’) located at the end of the SEC13 gene (TriTrypDB Tb927.10.14180)
and the reverse primer AQP3R. The PCR was performed with AccuTherm DNA polymerase
with the followings parameters: 1 cycle of 95°C for 2 min and 35 cycles of (95°C, 50 s; 50°C, 50
s; 72°C, 6.5 min). PCR products were run on a 0.8% agarose gel and purified on a silica mem-
brane column (Nucleospin gel and PCR clean up, Macherey Nagel). The purified bands were
directly sequenced with different combinations of the above primers to cover the complete se-
quence of the locus.
Real time quantitative reverse transcription PCR (real-time qRT-PCR)
Trypanosomes were harvested in 1 mL TRIzol reagent (Invitrogen) and total RNA was isolated
following manufacturer’s protocol. First strand cDNA synthesis was performed using Super-
Script III Reverse Transcriptase (Invitrogen) and Oligo dT20 as primer. Quantitative PCR am-
plification was performed using SYBR Green Master Mix (Bio Rad). The levels of TbAT1
mRNA were normalized against actin mRNA and the relative quantification was calculated by
the ΔΔCT method. Primers for TbAT1 were AT1_863F (5’ CGA CTT CGC AGC AGA TGT
TAA TG 3’) and AT1_956R (5’ CGG CAG GGT AGA CGA GAA ATG 3’), For actin the prim-
er used were ACT206F (5’ AAT GAG CAA GCG ATG ATG GG 3’) and ACT348R (5’ GCA
ACT CGT TAT AGA AGG TAT GG 3’) [53]. Thermal cycling was carried out as follows: 1
cycle of 95°C for 5 min and 40 cycles of (95°C, 15 s; 60°C, 60 s).
Supporting Information
S1 Fig. Release of pentamidine from NbAn33-pentamidine-chNPs as a function of the in-
cubation time and pH.
(TIF)
S2 Fig. IC50 curves analysis. Error bars, S.D. from 3–9 independent experiments. Testing pent-
amidine, pentamidine-chNPs (pentamidine-loaded PEGlycated chitosan nanoparticles),
NbAn33-pentamidine-chNPs (nanobody-coated pentamidine-loaded PEGlycated chitosan
nanoparticles), NbAn33-chNPs empty (nanobody-coated PEGlycated-chitosan nanoparticles)
and chNPs-empty (PEGlycated chitosan nanoparticles).
(TIF)
S3 Fig. Analysis of AQP2/3 locus from wild type AnTat1.1 and TbR25 showing the struc-
ture of both alleles in the latter. Top, PCR amplification strategy of AQP2, AQP3 and the en-
tire locus. Bottom, nucleotide sequence of AQP3/AQP2 chimeric gene (Genbank accession
number: KR059026). Bold indicates 453 nucleotides corresponding to AQP3 (Aquaglycero-
porin 3) (TriTrypDB Tb927.10.14160); underlying indicates 462 nucleotides corresponding to
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AQP2 (Aquaglyceroporin 2) (TriTrypDB Tb927.10.14170); grey indicates primers binding site;
numbers indicate the position in chromosome 10 (Tb927_10_v5; strain 927 chromosome 10,
version 5).
(TIF)
S1 Table. Effect of formulation conditions on nanoparticles parameters.
(DOCX)
S2 Table. Blood compatibility assays. Blood compatibility of pentamidine unloaded PEGy-
lated chitosan nanoparticles (chNPs-empty), pentamidine-loaded PEGlycated chitosan nano-
particles (pentamidine-chNPs), nanobody-coated PEGlycated-chitosan nanoparticles
(NbAn33-chNPs) and nanobody-coated pentamidine-loaded PEGlycated chitosan nanoparti-
cles (NbAn33-pentamidine-chNPs) in terms of hemolysis (%), platelet activation (sP-selectin
release, ngmL-1), complement activation (C3a release: C3a desArg, ngmL-1), and plasma
recalcification time (T1/2 max, min). For drug delivery applications hemolysis value 2.9% is
considered hemocompatible.
(DOCX)
Acknowledgments
The authors thank to Derek P Nolan for comments on the draft manuscript, Teresa del Castillo
and Carlos Rodrigues-Poveda for helpful discussion and Raquel Marrero and Lucía Perales-
Azor for technical support.
Author Contributions
Conceived and designed the experiments: JDUB JLA MS JAGS. Performed the experiments:
JDUB JLA JMMSMOG. Analyzed the data: JDUB JLA JMMSMOG JHQMMT HPdK SM
JAGS. Contributed reagents/materials/analysis tools: JHQMMT SM. Wrote the paper: JDUB
JLA MS JAGS.
References
1. Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, et al. The trypanosomiases.
Lancet. 2003; 362(9394):1469–80. Epub 2003/11/07. S0140-6736(03)14694-6 [pii]; doi: 10.1016/
S0140-6736(03)14694-6 PMID: 14602444.
2. Brun R, Blum J. Human african trypanosomiasis. Infect Dis Clin North Am. 2012; 26(2):261–73. Epub
2012/05/29. S0891-5520(12)00012-8 [pii] doi: 10.1016/j.idc.2012.03.003 PMID: 22632638.
3. Glover L, Hutchinson S, Alsford S, McCulloch R, Field MC, Horn D. Antigenic variation in African try-
panosomes: the importance of chromosomal and nuclear context in VSG expression control. Cell
Microbiol. 2013. Epub 2013/09/21. doi: 10.1111/cmi.12215 PMID: 24047558.
4. Priotto G, Kasparian S, MutomboW, Ngouama D, Ghorashian S, Arnold U, et al. Nifurtimox-eflornithine
combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a mul-
ticentre, randomised, phase III, non-inferiority trial. Lancet. 2009; 374(9683):56–64. Epub 2009/06/30.
S0140-6736(09)61117-X [pii] doi: 10.1016/S0140-6736(09)61117-X PMID: 19559476.
5. Delespaux V, de Koning HP. Drugs and drug resistance in African trypanosomiasis. Drug Resist Updat.
2007; 10(1–2):30–50. Epub 2007/04/06. S1368-7646(07)00021-0 [pii] doi: 10.1016/j.drup.2007.02.004
PMID: 17409013.
6. Arias JL. Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery sys-
tems. Molecules. 2008; 13(10):2340–69. Epub 2008/10/03. 13102340 [pii]. PMID: 18830159.
7. Unciti-Broceta JD, Del Castillo T, Soriano M, Magez S, Garcia-Salcedo JA. Novel therapy based on
camelid nanobodies. Therapeutic delivery. 2013; 4(10):1321–36. Epub 2013/10/15. doi: 10.4155/tde.
13.87 PMID: 24116915.
8. Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, Senter P, et al. Efficient targeting
of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes
Overcoming Drug Resistance in African Trypanosomiasis
PLOS Pathogens | DOI:10.1371/journal.ppat.1004942 June 25, 2015 17 / 20
as paradigm. J Biol Chem. 2004; 279(2):1256–61. Epub 2003/10/07. doi: 10.1074/jbc.M307341200
M307341200 [pii]. PMID: 14527957.
9. Baral TN, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, et al. Experimental therapy of
African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med. 2006; 12
(5):580–4. Epub 2006/04/11. nm1395 [pii] doi: 10.1038/nm1395 PMID: 16604085.
10. Magez S, Radwanska M, Stijlemans B, Xong HV, Pays E, De Baetselier P. A conserved flagellar pocket
exposed high mannose moiety is used by African trypanosomes as a host cytokine binding molecule. J
Biol Chem. 2001; 276(36):33458–64. Epub 2001/06/19. doi: 10.1074/jbc.M103412200 M103412200
[pii]. PMID: 11404356.
11. Arias JL, Unciti-Broceta JD, Maceira J, Del Castillo T, Hernandez-Quero J, Magez S, et al. Nanobody
conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis. J Control Release.
2015; 197:190–8. Epub 2014/12/03. S0168-3659(14)00739-1 [pii] doi: 10.1016/j.jconrel.2014.11.002
PMID: 25445702.
12. Arias JL. Advanced methodologies to formulate nanotheragnostic agents for combined drug delivery
and imaging. Expert Opin Drug Deliv. 2011; 8(12):1589–608. Epub 2011/11/22. doi: 10.1517/
17425247.2012.634794 PMID: 22097904.
13. Arias JL, Reddy LH, Couvreur P. Superior preclinical efficacy of gemcitabine developed as chitosan
nanoparticulate system. Biomacromolecules. 2011; 12(1):97–104. Epub 2010/12/02. doi: 10.1021/
bm101044h PMID: 21117615.
14. Malhotra M, Tomaro-Duchesneau C, Prakash S. Synthesis of TAT peptide-tagged PEGylated chitosan
nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials. 2013; 34
(4):1270–80. doi: 10.1016/j.biomaterials.2012.10.013 PMID: 23140978
15. Torrecilla D, Lozano MV, Lallana E, Neissa JI, Novoa-Carballal R, Vidal A, et al. Anti-tumor efficacy of
chitosan-g-poly(ethylene glycol) nanocapsules containing docetaxel: Anti-TMEFF-2 functionalized
nanocapsules vs. non-functionalized nanocapsules. European Journal of Pharmaceutics and Biophar-
maceutics. 2013; 83(3):330–7. doi: 10.1016/j.ejpb.2012.10.017 PMID: 23262164
16. Thuita JK, Karanja SM, Wenzler T, Mdachi RE, Ngotho JM, Kagira JM, et al. Efficacy of the diamidine
DB75 and its prodrug DB289, against murine models of human African trypanosomiasis. Acta Trop.
2008; 108(1):6–10. Epub 2008/08/30. S0001-706X(08)00210-6 [pii] doi: 10.1016/j.actatropica.2008.
07.006 PMID: 18722336.
17. Frearson JA, Brand S, McElroy SP, Cleghorn LA, Smid O, Stojanovski L, et al. N-myristoyltransferase
inhibitors as new leads to treat sleeping sickness. Nature. 2010; 464(7289):728–32. Epub 2010/04/03.
nature08893 [pii] doi: 10.1038/nature08893 PMID: 20360736; PubMed Central PMCID: PMC2917743.
18. Stijlemans B, Caljon G, Natesan SK, Saerens D, Conrath K, Perez-Morga D, et al. High affinity nanobo-
dies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLoS
Pathog. 2011; 7(6):e1002072. Epub 2011/06/24. doi: 10.1371/journal.ppat.1002072 10-PLPA-RA-
4101 [pii]. PMID: 21698216; PubMed Central PMCID: PMC3116811.
19. Caljon G, Stijlemans B, Saerens D, Van Den Abbeele J, Muyldermans S, Magez S, et al. Affinity is an
important determinant of the anti-trypanosome activity of nanobodies. PLoS Negl Trop Dis. 2012; 6
(11):e1902. Epub 2012/11/21. doi: 10.1371/journal.pntd.0001902 PNTD-D-12-00780 [pii]. PMID:
23166849; PubMed Central PMCID: PMC3499403.
20. De Vooght L, Caljon G, Stijlemans B, De Baetselier P, Coosemans M, Van den Abbeele J. Expression
and extracellular release of a functional anti-trypanosome Nanobody(R) in Sodalis glossinidius, a bac-
terial symbiont of the tsetse fly. Microb Cell Fact. 2012; 11:23. Epub 2012/02/18. 1475-2859-11-23 [pii]
doi: 10.1186/1475-2859-11-23 PMID: 22335892; PubMed Central PMCID: PMC3311065.
21. Nolan DP, Geuskens M, Pays E. N-linked glycans containing linear poly-N-acetyllactosamine as sort-
ing signals in endocytosis in Trypanosoma brucei. Curr Biol. 1999; 9(20):1169–72. Epub 1999/10/26.
S0960-9822(00)80018-4 [pii] doi: 10.1016/S0960-9822(00)80018-4 PMID: 10531030.
22. Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, Leung KF, et al. High-throughput decoding
of antitrypanosomal drug efficacy and resistance. Nature. 2012; 482(7384):232–6. Epub 2012/01/27.
nature10771 [pii] doi: 10.1038/nature10771 PMID: 22278056; PubMed Central PMCID: PMC3303116.
23. Bernhard SC, Nerima B, Maser P, Brun R. Melarsoprol- and pentamidine-resistant Trypanosoma bru-
cei rhodesiense populations and their cross-resistance. Int J Parasitol. 2007; 37(13):1443–8. Epub
2007/07/03. S0020-7519(07)00180-4 [pii] doi: 10.1016/j.ijpara.2007.05.007 PMID: 17602691.
24. Carter NS, Berger BJ, Fairlamb AH. Uptake of diamidine drugs by the P2 nucleoside transporter in mel-
arsen-sensitive and-resistant Trypanosoma brucei brucei. J Biol Chem. 1995; 270(47):28153–7. Epub
1995/11/24. PMID: 7499305.
25. Baker N, Glover L, Munday JC, Aguinaga Andres D, Barrett MP, de Koning HP, et al. Aquaglyceroporin
2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc Natl Acad Sci U
S A. 2012. Epub 2012/06/20. 1202885109 [pii] doi: 10.1073/pnas.1202885109 PMID: 22711816.
Overcoming Drug Resistance in African Trypanosomiasis
PLOS Pathogens | DOI:10.1371/journal.ppat.1004942 June 25, 2015 18 / 20
26. Bridges DJ, Gould MK, Nerima B, Maser P, Burchmore RJ, de Koning HP. Loss of the high-affinity pent-
amidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine
drugs in African trypanosomes. Mol Pharmacol. 2007; 71(4):1098–108. Epub 2007/01/20.
mol.106.031351 [pii] doi: 10.1124/mol.106.031351 PMID: 17234896.
27. Graf FE, Ludin P, Wenzler T, Kaiser M, Brun R, Pyana PP, et al. Aquaporin 2 Mutations in Trypano-
soma brucei gambiense Field Isolates Correlate with Decreased Susceptibility to Pentamidine and Mel-
arsoprol. PLoS Negl Trop Dis. 2013; 7(10):e2475. doi: 10.1371/journal.pntd.0002475 PMID: 24130910
28. Munday JC, Eze AA, Baker N, Glover L, Clucas C, Aguinaga Andres D, et al. Trypanosoma brucei
aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs
and the main genetic determinant of resistance to these drugs. The Journal of antimicrobial chemother-
apy. 2013. Epub 2013/11/16. doi: 10.1093/jac/dkt442 PMID: 24235095.
29. de Koning HP, Anderson LF, Stewart M, Burchmore RJ, Wallace LJ, Barrett MP. The trypanocide
diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional
insights on diamidine resistance in african trypanosomes. Antimicrob Agents Chemother. 2004; 48
(5):1515–9. Epub 2004/04/24. PMID: 15105099; PubMed Central PMCID: PMC400564.
30. Munday JC, Rojas Lopez KE, Eze AA, Delespaux V, Van Den Abbeele J, Rowan T, et al. Functional ex-
pression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene
uptake. Int J Parasitol Drugs Drug Resist. 2013; 3:69–76. Epub 2014/02/18. doi: 10.1016/j.ijpddr.2013.
01.004 S2211-3207(13)00005-5 [pii]. PMID: 24533295; PubMed Central PMCID: PMC3862423.
31. Munday JC, Tagoe DN, Eze AA, Krezdorn JA, Rojas Lopez KE, Alkhaldi AA, et al. Functional analysis
of drug resistance-associated mutations in the Trypanosoma brucei adenosine transporter 1 (TbAT1)
and the proposal of a structural model for the protein. Mol Microbiol. 2015. Epub 2015/02/25. doi: 10.
1111/mmi.12979 PMID: 25708978.
32. Munday JC, Settimo L, de Koning HP. Transport proteins determine drug sensitivity and resistance in a
protozoan parasite, Trypanosoma brucei. Front Pharmacol. 2015; 6:32. Epub 2015/03/31. doi: 10.
3389/fphar.2015.00032 PMID: 25814953; PubMed Central PMCID: PMC4356943.
33. Barrett MP, Vincent IM, Burchmore RJS, Kazibwe AJN, Matovu E. Drug resistance in human African
trypanosomiasis. Future Microbiology. 2011; 6(9):1037–47. doi: 10.2217/fmb.11.88 PMID: 21958143
34. Garcia-Salcedo J, Munday J, Unciti-Broceta J, Koning H. Progress Towards New Treatments for
Human African Trypanosomiasis. In: Magez S, Radwanska M, editors. Trypanosomes and Trypanoso-
miasis: Springer Vienna; 2014. p. 217–38.
35. Mäser P, Wittlin S, Rottmann M, Wenzler T, Kaiser M, Brun R. Antiparasitic agents: new drugs on the
horizon. Current Opinion in Pharmacology. 2012; 12(5):562–6. doi: 10.1016/j.coph.2012.05.001 PMID:
22652215
36. Vanaerschot M, Huijben S, Van den Broeck F, Dujardin JC. Drug resistance in vectorborne parasites:
multiple actors and scenarios for an evolutionary arms race. FEMSMicrobiol Rev. 2013. Epub 2013/07/
03. doi: 10.1111/1574-6976.12032 PMID: 23815683.
37. Vincent IM, Creek D, Watson DG, Kamleh MA, Woods DJ, Wong PE, et al. A molecular mechanism for
eflornithine resistance in African trypanosomes. PLoS Pathog. 2010; 6(11):e1001204. Epub 2010/12/
03. doi: 10.1371/journal.ppat.1001204 PMID: 21124824; PubMed Central PMCID: PMC2991269.
38. Schumann Burkard G, Jutzi P, Roditi I. Genome-wide RNAi screens in bloodstream form trypanosomes
identify drug transporters. Mol Biochem Parasitol. 2011; 175(1):91–4. Epub 2010/09/21. S0166-6851
(10)00233-1 [pii] doi: 10.1016/j.molbiopara.2010.09.002 PMID: 20851719.
39. Carter NS, Fairlamb AH. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Na-
ture. 1993; 361(6408):173–6. Epub 1993/01/14. doi: 10.1038/361173a0 PMID: 8421523.
40. Maser P, Sutterlin C, Kralli A, Kaminsky R. A nucleoside transporter from Trypanosoma brucei involved
in drug resistance. Science. 1999; 285(5425):242–4. Epub 1999/07/10. 7645 [pii]. PMID: 10398598.
41. Matovu E, Stewart ML, Geiser F, Brun R, Maser P, Wallace LJ, et al. Mechanisms of arsenical and dia-
midine uptake and resistance in Trypanosoma brucei. Eukaryot Cell. 2003; 2(5):1003–8. Epub 2003/
10/14. PMID: 14555482; PubMed Central PMCID: PMC219364.
42. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan
and its derivatives. Advanced Drug Delivery Reviews. 2010; 62(1):28–41. doi: 10.1016/j.addr.2009.10.
003 PMID: 19874862
43. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, et al. Chitosan microspheres as a
potential carrier for drugs. International Journal of Pharmaceutics. 2004; 274(1–2):1–33. doi: 10.1016/j.
ijpharm.2003.12.026 PMID: 15072800
44. Manca ML, Loy G, Zaru M, Fadda AM, Antimisiaris SG. Release of rifampicin from chitosan, PLGA and
chitosan-coated PLGAmicroparticles. Colloids and Surfaces B: Biointerfaces. 2008; 67(2):166–70. doi:
10.1016/j.colsurfb.2008.08.010 PMID: 18835764
Overcoming Drug Resistance in African Trypanosomiasis
PLOS Pathogens | DOI:10.1371/journal.ppat.1004942 June 25, 2015 19 / 20
45. Durand R, Paul M, Rivollet D, Houin R, Astier A, Deniau M. Activity of pentamidine-loaded methacrylate
nanoparticles against Leishmania infantum in a mouse model. International Journal for Parasitology.
1997; 27(11):1361–7. doi: 10.1016/S0020-7519(97)00124-0 PMID: 9421724
46. Fusai T, Deniau M, Durand R, Bories C, Paul M, Rivollet D, et al. Action of pentamidine-bound nanopar-
ticles against Leishmania on an in vivo model. Parasite (Paris, France). 1994; 1(4):319–24. PMID:
9140499
47. Durand R, Paul M, Rivollet D, Fessi H, Houin R, Astier A, et al. Activity of pentamidine-loaded poly (D,L-
lactide) nanoparticles against Leishmania infantum in a murine model. Parasite. 1997; 4(4):331–6.
PMID: 9587601
48. Hirumi H, Hirumi K. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium con-
taining a low concentration of serum protein without feeder cell layers. The Journal of parasitology.
1989; 75(6):985–9. Epub 1989/12/01. PMID: 2614608.
49. Dash BC, Réthoré G, MonaghanM, Fitzgerald K, Gallagher W, Pandit A. The influence of size and
charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood com-
patibility. Biomaterials. 2010; 31(32):8188–97. doi: 10.1016/j.biomaterials.2010.07.067 PMID:
20701967
50. Unciti-Broceta JD, Maceira J, Morales S, Garcia-Perez A, Munoz-Torres ME, Garcia-Salcedo JA. Nico-
tinamide inhibits the lysosomal cathepsin b-like protease and kills African trypanosomes. J Biol Chem.
2013. Epub 2013/02/28. M112.449207 [pii] doi: 10.1074/jbc.M112.449207 PMID: 23443665.
51. Kourtis IC, Hirosue S, de Titta A, Kontos S, Stegmann T, Hubbell JA, et al. Peripherally Administered
Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice.
PLoS ONE. 2013; 8(4):e61646. doi: 10.1371/journal.pone.0061646 PMID: 23626707
52. Stewart ML, Burchmore RJ, Clucas C, Hertz-Fowler C, Brooks K, Tait A, et al. Multiple genetic mecha-
nisms lead to loss of functional TbAT1 expression in drug-resistant trypanosomes. Eukaryot Cell. 2010;
9(2):336–43. Epub 2009/12/08. EC.00200-09 [pii] doi: 10.1128/EC.00200-09 PMID: 19966032;
PubMed Central PMCID: PMC2823006.
53. Spitznagel D, Ebikeme C, Biran M, Nic a' Bhaird N, Bringaud F, Henehan GT, et al. Alanine aminotrans-
ferase of Trypanosoma brucei—a key role in proline metabolism in procyclic life forms. FEBS J. 2009;
276(23):7187–99. Epub 2009/11/10. EJB7432 [pii] doi: 10.1111/j.1742-4658.2009.07432.x PMID:
19895576.
Overcoming Drug Resistance in African Trypanosomiasis
PLOS Pathogens | DOI:10.1371/journal.ppat.1004942 June 25, 2015 20 / 20
